FUNDRAISING through initial public offerings (IPOs) has continued in India as three firms are looking to collectively mop up about Rs 210 billion (£2.1 bn) this week.
One97 Communications, the owner of payment major Paytm, launched its Rs 183-billion (£1.83 bn) IPO on Monday (8) and its shares were subscribed 48 per cent till the end of the day two on Tuesday (9).
Sapphire Foods India, which operates KFC and Pizza Hut outlets, began its share sale on Tuesday (9) and its offer was subscribed 30 per cent till the end of the day.
A third firm, Latent View Analytics, is set to approach the primary market on Wednesday (10).
This comes after five companies successfully concluded their IPOs last week.
These were FSN E-Commerce Ventures, which runs an online marketplace for beauty and wellness products Nykaa; Fino Payments Bank; Policybazaar parent entity PB Fintech; decorative aesthetics supplier SJS Enterprises; and microcrystalline cellulose maker Sigachi Industries.
So far in 2021, as many as 46 companies have floated their IPOs to raise Rs 801 bn (£8 bn) and market experts believe that the year could close with a Rs 1 trillion (£9.98 bn) primary market fundraising.
In addition, PowerGrid InvIT, the infrastructure investment trust (InvIT) sponsored by the Power Grid Corporation of India, mopped up Rs 77.3 bn (£770 million) through its IPO, and Brookfield India Real Estate Trust raised Rs 38 bn (£380m) via its initial share-sale.
Until now, fundraising this year is higher than the Rs 266 bn (2.6 bn) collected by 15 companies through initial share-sales in the entire 2020.
Such fundraising through IPOs was last seen in 2017 when firms mobilised Rs 671 bn (£6.7 bn) through 36 initial share-sales.
One97 Communications has fixed a price band of Rs 2,080-2,150 (£2.77-21.47) apiece, implying a valuation of around Rs 1.48 trillion (£14.7 bn). The Rs 18.3-bn (£180m) offer, if successful, will be the biggest in the country after Coal India's IPO in 2010, wherein the state-owned company garnered Rs 152 bn (£1.52 bn).
The digital firm’s offering received bids for 23.4 million equity shares against the offer size of 48.3 million shares, according to information available from stock exchanges in Mumbai.
While retail investors lapped up the offering, qualified institutional buyers (QIBs), including FIIs, have so far shown less than enthusiastic participation.
QIBs have the largest number of shares reserved for them at 26.3 million. Against this, bids were received for 12 million as of Tuesday (9).
The IPO was subscribed 18 per cent on the opening day. The offering closes on Wednesday (10) evening.
Other tech IPOs - such as those of Nykaa and Zomato Ltd - received stronger investor demand on their opening days, but they were much smaller compared to Paytm's share sale.
"The biggest merit for Paytm's IPO would be that they have so much more diversified regulatory access under one roof. This focus on diversification means that none of their particular business books has depth, unlike other major players who focus more on specialising," Nikhil Kamath, co-founder of True Beacon and Zerodha, said.
Last week, Paytm raised Rs 82.3 bn (£820m) from anchor investors.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.